From wiki:
Imugene began as a research project in the laboratory of Professor Ursula Wiedermann at the Medical University of Vienna. Over the nine years from 2004 Wiedermann et al. had developed a B cell peptide cancer immunotherapy that could induce an antibody response targeting HER-2 overexpressing tumours. In 2012 a start-up company called Biolife Science had been incorporated to develop this immunotherapy. Early-stage funding was secured from Australian and US investors in 2013, after which Biolife was taken public in December 2013 in a reverse takeover of an Australian drug development company called Imugene, whose name was retained after the merger
Charting Only., page-2349
-
-
- There are more pages in this discussion • 177 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMU (ASX) to my watchlist
(20min delay)
|
|||||
Last
5.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $420.8M |
Open | High | Low | Value | Volume |
5.9¢ | 5.9¢ | 5.6¢ | $1.006M | 17.41M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
23 | 2917286 | 5.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.9¢ | 849706 | 15 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
23 | 2917286 | 0.058 |
19 | 3410464 | 0.057 |
27 | 4797023 | 0.056 |
33 | 4801573 | 0.055 |
10 | 330000 | 0.054 |
Price($) | Vol. | No. |
---|---|---|
0.059 | 845041 | 15 |
0.060 | 2938645 | 20 |
0.061 | 969907 | 6 |
0.062 | 2227969 | 6 |
0.063 | 243179 | 3 |
Last trade - 15.45pm 21/06/2024 (20 minute delay) ? |
Featured News
IMU (ASX) Chart |
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
SPONSORED BY The Market Online